Literature DB >> 12554752

Molecular basis for the subtype discrimination of the estrogen receptor-beta-selective ligand, diarylpropionitrile.

Jun Sun1, Jerome Baudry, John A Katzenellenbogen, Benita S Katzenellenbogen.   

Abstract

Although the two subtypes of the human estrogen receptor (ER), ERalpha and ERbeta, share only 56% amino acid sequence identity in their ligand binding domain (LBD), the residues that surround the ligand are nearly identical; nevertheless, subtype-selective ligands are known. To understand the molecular basis by which diarylpropionitrile (DPN), an ERbeta-selective ligand, is able to discriminate between the two ERs, we examined its activity on ER mutants and chimeric constructs generated by DNA shuffling. The N-terminal region of the ERbeta LBD (through helix 6) appears to be fully responsible for the ERbeta selectivity of DPN. In fact, a single ERalpha point mutation (L384M) was largely sufficient to switch the DPN response of this ER to that of the ERbeta type, but residues in helix 3 are also important in achieving the full ERbeta selectivity of DPN. Using molecular modeling, we found an energetically favorable fit for the S-DPN enantiomer in ERbeta, in which the proximal phenol mimics the A ring of estradiol, and the nitrile engages in stabilizing interactions with residues in the ligand-binding pocket of ERbeta. Our findings highlight that a limited number of critical interactions of DPN with the ERbeta ligand-binding pocket underlie its ER subtype-selective character.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554752     DOI: 10.1210/me.2002-0341

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  24 in total

1.  Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β.

Authors:  Han Liu; Ali Pedram; Jin Kyung Kim
Journal:  Cardiovasc Res       Date:  2010-08-19       Impact factor: 10.787

Review 2.  Laboratory-directed protein evolution.

Authors:  Ling Yuan; Itzhak Kurek; James English; Robert Keenan
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

3.  Effects of selective estrogen receptor alpha and beta modulators on prepulse inhibition in male mice.

Authors:  Marie A Labouesse; Wolfgang Langhans; Urs Meyer
Journal:  Psychopharmacology (Berl)       Date:  2015-04-18       Impact factor: 4.530

4.  Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.

Authors:  Vincent M Carroll; M Jeyakumar; Kathryn E Carlson; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2011-12-14       Impact factor: 7.446

Review 5.  Selectively targeting estrogen receptors for cancer treatment.

Authors:  Erin K Shanle; Wei Xu
Journal:  Adv Drug Deliv Rev       Date:  2010-08-10       Impact factor: 15.470

6.  Biphenyl C-cyclopropylalkylamides: New scaffolds for targeting estrogen receptor beta.

Authors:  Miranda J Sarachine; Jelena M Janjic; Peter Wipf; Billy W Day
Journal:  Bioorg Med Chem Lett       Date:  2009-03-25       Impact factor: 2.823

7.  Differential regulation of gonadotropin-releasing hormone neuron activity and membrane properties by acutely applied estradiol: dependence on dose and estrogen receptor subtype.

Authors:  Zhiguo Chu; Josefa Andrade; Margaret A Shupnik; Suzanne M Moenter
Journal:  J Neurosci       Date:  2009-04-29       Impact factor: 6.167

Review 8.  Estrogen receptor beta in the brain: from form to function.

Authors:  Michael J Weiser; Chad D Foradori; Robert J Handa
Journal:  Brain Res Rev       Date:  2007-06-26

Review 9.  Understanding nuclear receptor form and function using structural biology.

Authors:  Fraydoon Rastinejad; Pengxiang Huang; Vikas Chandra; Sepideh Khorasanizadeh
Journal:  J Mol Endocrinol       Date:  2013-11-07       Impact factor: 5.098

10.  Structural features of diverse ligands influencing binding affinities to estrogen alpha and estrogen beta receptors. Part I: Molecular descriptors calculated from minimal energy conformation of isolated ligands.

Authors:  Elena Boriani; Morena Spreafico; Emilio Benfenati; Marjana Novic
Journal:  Mol Divers       Date:  2008-03-05       Impact factor: 2.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.